KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Free Cash Flow (2016 - 2025)

Abbott Laboratories' Free Cash Flow history spans 17 years, with the latest figure at $2.6 billion for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 22.25% year-over-year to $2.6 billion; the TTM value through Dec 2025 reached $7.4 billion, up 16.44%, while the annual FY2025 figure was $7.4 billion, 16.44% up from the prior year.
  • Free Cash Flow for Q4 2025 was $2.6 billion at Abbott Laboratories, up from $2.3 billion in the prior quarter.
  • Across five years, Free Cash Flow topped out at $2.6 billion in Q4 2025 and bottomed at $627.0 million in Q1 2024.
  • The 5-year median for Free Cash Flow is $1.9 billion (2022), against an average of $1.8 billion.
  • The largest annual shift saw Free Cash Flow soared 530.99% in 2021 before it tumbled 65.73% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at $2.5 billion in 2021, then tumbled by 30.04% to $1.7 billion in 2022, then soared by 33.04% to $2.3 billion in 2023, then decreased by 5.91% to $2.1 billion in 2024, then increased by 22.25% to $2.6 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Free Cash Flow are $2.6 billion (Q4 2025), $2.3 billion (Q3 2025), and $1.5 billion (Q2 2025).